Committees

Charter

The ISCT Global Industry Committee serves as the strategic leadership body of the ISCT Industry Pillar. It engages commercial sector leaders to address critical challenges in the development and commercialization of cell and gene therapies (CGT). The Committee acts as a global communication hub—connecting therapeutic societies, regulatory policymakers, institutional stem cell centers, and industry stakeholders—to advance clinical investigation in cell therapy and regenerative medicine. With input from key opinion leaders and experts across the CGT value chain, the Committee explores sector trends, financial and business development topics, and current events. It also works to identify and overcome industry barriers to market access, driving meaningful progress in the field.

2025 Projects & Objectives

• Webinar : Follow the Money: Understanding CAR-T Reimbursement.
• Multi-Chapter Publication: Barriers to Global Access; Reimbursement, Translational Challenges, Clinical Access & Valuation.
• ISCT 2025 Roundtable: What is Wrong with the current definition of Value
• ISCT 2025 Roundtable: Redefining Reimbursement: A Global Perspective
• Roadmap : From Academic Spin out to Industry Start up
• Commercialisation Signature Series 2025 : Accelerating Patient Access to Products – Enabling the Industrialization of CGT.

Recent Publications

• Artificial intelligence, machine learning, and digitalization systems in the cell and gene therapy sector: a guidance document from the ISCT industry committees

The Committee

Chair

Phil Vanek, PhD

Gamma Biosciences
United States

2025 Members

Mark Flower
AGC Biologics 

David Smith
Akron Biotech

Patrick Rivers
Amoon Fund

Adrienne Mendoza
BioBridge Global

Aby J. Mathew
BioLife Solutions

Sophie He
Bracco

Ali Soleymannezhad
Cellares

Mattew Hewitt
Charles River Laboratories

Dominic Clarke
Cryoport

Aruna Mor
Cryoport

Martin Westberg
Cytiva

Oliver Ball
Dark Horse Consulting

Vincenzo Di Cerbo
CGT Catapult

Yoshie Tsurumaki
FIRM

Antonio Scatena
Gateway Analytical

Phil Vanek
Redline Bio

Tony Ting
Kiji Therapeutics

Miguel Forte
Kiji Therapeutics

Behnam Ahmadian
Lonza

Sean Hart
LumaCyte

Julie Allickson
Mayo Clinic

Antonio Lee
Medipost

Caroline Blumer Toti
Miltenyi Biotec

Eytan Abraham
Minaris Advanced Therapies

Beth San Segundo
OriGen Biomedical

Priya Baraniak 
PluristyX

Lindsay Davies 
Qvance

Maya Fuerstenau-Sharp
Sartorius Stedim Biotech GmbH

Jennnifer Solomon
STEMCELL Technologies

Sven Kili
Saeisei Ventures

Veerle D'Haenens
Terumo BCT

Uma Lakshmipathy
Thermo Fisher Scientific

Bruce Levine
University of Pennsylvania School of Medicine

Becky Butler Cap
Vitalant